Zanamivir, marketed under the brand name Relenza, is an antiviral medication used to treat and prevent influenza A and B. It was developed by the pharmaceutical company GlaxoSmithKline and received FDA approval in 1999. Zanamivir is a neuraminidase inhibitor, which means it blocks the function of the viral neuraminidase protein, thereby preventing the virus from replicating within the human body.
